Likewise, in a study by Holmgaard et al., it was found that the combination of inhibition of the TGFβ1 pathway and anti-PD-L1 therapy showed a strong anti-tumor efficacy, causing inhibition of tumor growth and complete regression in colon carcinoma models (Holmgaard et al., 2018). This evidence concerns the gene TGFB1 and neoplasm.